文献速递其他结缔组织病

IL-4受体α阻断治疗局限性硬皮病:一项2期概念验证研究

Interleukin 4-receptor-α blockade in localised scleroderma: a phase 2 proof-of-concept study.
PubMed 文献 · Ann Rheum Dis · 2026-10-29

该随机安慰剂对照2期试验研究阻断IL-4受体α(dupilumab)治疗局限性硬皮病(LS)6个月的效果。结果显示,与安慰剂相比,dupilumab显著改善临床症状、减轻局部炎症、降低IL-4/IL-13依赖基因签名并部分抑制促纤维化基因。结论认为选择性抑制IL-4/IL-13可阻止LS进展,对其他纤维化疾病有治疗预防前景。

要点

  • dupilumab阻断IL-4受体α治疗LS 6个月,临床改善显著优于安慰剂。
  • 治疗显著减轻局部炎症并降低IL-4/IL-13依赖基因签名。
  • 部分抑制编码促纤维化蛋白的基因,支持抗纤维化作用。

核心结论

  • 选择性抑制IL-4/IL-13可阻止局限性硬皮病进展,并对其他纤维化疾病的治疗预防具有前景。

研究设计与样本

  • 随机、安慰剂对照的2期概念验证临床试验(ClinicalTrials.gov注册号NCT04200755),研究dupilumab阻断IL-4受体α 6个月对局限性硬皮病疾病进展、硬化相关炎症及硬化特异性基因表达的影响。

主要发现

  • 短期干预即带来显著优于安慰剂的临床改善。
  • 显著减轻局部炎症。
  • 特异性且显著降低IL-4/IL-13依赖基因签名。
  • 部分抑制编码促纤维化蛋白的基因。

临床怎么用

  • 在局限性硬皮病患者中,可考虑使用dupilumab阻断IL-4受体α以改善临床和炎症指标,但需进一步验证。

局限性

  • 原文未报告样本量、具体效应值、P值及置信区间。
  • 仅为2期概念验证研究,短期干预,结论需更长期和大样本研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Fibrotic diseases are a major therapeutic challenge. In humans, fibrosing diseases are often associated with an interleukin (IL-) 4/TH2 signature. In preclinical mouse models, development of fibrosis critically depends on IL-4/signal transducer and activator of transcription 6 (STAT6). Yet, the role of IL-4/IL-13 in human fibrosing diseases remains unknown, and treatment development requires a deeper understanding of the role of IL-4/IL-13 in the pathogenesis. The local inflammation and the development of fibrosis in localised scleroderma (LS) are similar to those in systemic sclerosis and other fibrosing diseases. METHODS: In this article, we investigated the role of IL-4/IL-13 signalling in LS in a randomised, placebo-controlled clinical trial (ClinicalTrials.gov registration: NCT04200755). We studied the effect of 6 months of blocking IL-4-receptor α with dupilumab on disease progression, sclerosis-associated inflammation, and sclerosis-specific gene expression. RESULTS: Already this short-term intervention resulted in a significant clinical improvement over placebo, a significant attenuation of the local inflammation, a specific and significant reduction of the IL-4/IL-13-dependent gene signature, and a partial suppression of genes coding for fibrosis-inducing proteins. CONCLUSIONS: Thus, selective inhibition of IL-4/IL-13 prevents the progression of LS and is promising for therapeutic prevention of other fibrosing diseases.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Eming SA, Kreuter A, Hahn M, et al. Interleukin 4-receptor-α blockade in localised scleroderma: a phase 2 proof-of-concept study. Ann Rheum Dis. 2026. PMID: 42957460. doi:10.1016/j.ard.2026.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。